Lantheus (LNTH) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 22.5% year-over-year to $394.1 million, led by strong PYLARIFY, DEFINITY, and TechneLite sales, with PYLARIFY maintaining leadership in PSMA PET imaging.

• Adjusted EPS increased 16.4% to $1.80, while GAAP EPS declined to $0.88 due to higher R&D and G&A expenses.

• Major strategic acquisitions and licensing deals completed, including NAV-4694 for Alzheimer's, RM2 for oncology, and Radiopharm assets.

• CEO transition completed in March 2024, with Brian Markison appointed as CEO.

Financial highlights

• Q2 2024 consolidated net revenue was $394.1 million, up 22.5% year-over-year; PYLARIFY sales grew 29.8% to $273.3 million, DEFINITY sales up 10.7% to $78.1 million, and TechneLite revenue was $28.2 million, up 30.5%.

• Adjusted net income for Q2 2024 was $126.8 million, up 15.7% year-over-year; adjusted net income margin was 32.2%.

• Free cash flow for Q2 2024 was $73.5 million, up $116.5 million year-over-year; cash and equivalents stood at $757 million as of June 30, 2024.

• Operating profit was $171 million, up 14%; adjusted operating income margin was 43.4%.

• GAAP net income for Q2 2024 was $62.1 million, down from $94.1 million in Q2 2023, primarily due to higher R&D and G&A expenses.

Outlook and guidance

• Full-year 2024 consolidated revenue guidance affirmed at $1.5–1.52 billion, with PYLARIFY expected to grow in the mid-20% range.

• Adjusted EPS guidance revised to $6.60–6.70, reflecting increased R&D, higher share count, and impact of strategic transactions.

• Q3/Q4 revenue split expected to favor Q4 due to seasonal trends and strategic partnerships.

• NDA submission for MK-6240 expected in 2025; ongoing development of NAV-4694 and RM2 assets.

• No quarterly guidance; focus remains on full-year outlook and long-term growth.